Back to Results


Title A Randomized Trial of Levofloxacin to Prevent Bacteremia in Children Being Treated for Acute Leukemia (AL) or Undergoing Hematopoietic Stem Cell Transplantation (HSCT)
Therapeutic Area Leukemias (Pediatric)
Principal Investigator Michael J. Kelly, MD, MPH
Min Age 0 Years
Max Age 21 Years
Gender both
Contact Jennifer Truong
More Information


This study looks at how well an antibiotic prophylaxis, called levofloxacin, can prevent bacterial infection from developing in children and young adults receiving intensive cancer treatment or a stem cell transplant. The levofloxacin drug which prevents bacterial infection is experimental.

Study Details

Inclusion Criteria

  • Adequate renal function
  • Adequate creatinine clearance level

Exclusion Criteria

  • Patients with chronic active arthritis
  • Females who are pregnant or breast feeding.
  • Patients previously enrolled on the trial are not eligible.

Study Requirements

Subjects receiving a stem cell transplant may be on this study for up to 60 days. If you are an acute leukemia subject you may be on this study for up to 2 chemotherapy cycles lasting up to 60 days each. The time will depend on how long it takes for your neutrophil count to recover or until your study doctor decides to treat you for a new suspected or proven infection.  You will have follow-up examinations and medical tests at 2 and 12 months after treatment.